Cagrilintide · Research brief

Petrelintide vs Cagrilintide: Amylin Analogs Compared

Real Peptides Research TeamEditorial

Updated September 30, 20269 min read

52 WORDS

Short answer

The most consequential difference between these two research compounds isn't potency, and it isn't dosing frequency. It's which receptor each molecule deliberately leaves alone. Our team handles amylin-family peptides constantly, and the questions we field about petrelintide vs cagrilintide almost always start in the wrong place. Researchers ask which one is stronger.

Key takeaways

Petrelintide vs cagrilintide is fundamentally a selectivity comparison: petrelintide targets amylin receptors selectively, while cagrilintide also activates the calcitonin receptor.
Amylin signals through calcitonin receptor and RAMP complexes (AMY1, AMY2, AMY3) concentrated in the area postrema, not through incretin receptors.
Cagrilintide's phase 2 monotherapy data was published in The Lancet in 2021, and CagriSema combination results appeared in NEJM in 2025.
Petrelintide's phase 2b ZUPREME-1 topline was reported in 2025, and Zealand Pharma partnered with Roche the same year.
Native human amylin is amyloidogenic, so every analog in this class is engineered for solubility and is vulnerable to shear-induced aggregation during handling.
Cross-trial percentage comparisons between amylin and incretin compounds are statistically unsound because durations, titrations and populations differ.

The most consequential difference between these two research compounds isn't potency, and it isn't dosing frequency. It's which receptor each molecule deliberately leaves alone.

Our team handles amylin-family peptides constantly, and the questions we field about petrelintide vs cagrilintide almost always start in the wrong place. Researchers ask which one is stronger. The more useful question is which one is cleaner at the receptor.

Petrelintide vs cagrilintide: what is the actual difference?

Petrelintide vs cagrilintide comes down to receptor selectivity. Cagrilintide is a long-acting, non-selective amylin analog that also activates the calcitonin receptor. Petrelintide is engineered as a selective amylin receptor agonist. Both are investigational once-weekly compounds in metabolic research, and neither is an approved drug product.

The common oversimplification is that selectivity means weaker signalling. It doesn't. Selectivity changes which receptor populations get engaged and how fast they desensitise, which is a tolerability and durability question rather than a raw potency question. This piece covers the receptor biology behind petrelintide vs cagrilintide, what each compound's published record actually supports, how both sit against semaglutide, tirzepatide, retatrutide and eloralintide, and the handling quirks that ruin amylin peptides in the lab.

Two amylin analogs built on opposite receptor bets

Amylin, also called islet amyloid polypeptide (IAPP), is a 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells. It doesn't have a dedicated receptor of its own. Instead, it signals through complexes formed when the calcitonin receptor pairs with receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3), producing the AMY1, AMY2 and AMY3 receptor subtypes that are densely expressed in the area postrema of the brainstem. Research describes the downstream effects as satiation signalling, slowed gastric emptying and suppression of glucagon secretion.

Cagrilintide (development code AM833, Novo Nordisk) is a lipidated long-acting analog that activates both amylin and calcitonin receptors. Petrelintide (ZP8396, Zealand Pharma) was designed the other way: selective amylin receptor agonism with reduced calcitonin receptor activity. The working hypothesis in the literature is that calcitonin receptor engagement contributes to receptor desensitisation and to the nausea burden seen with non-selective agents. That is the entire scientific argument in petrelintide vs cagrilintide, stated plainly.

Here's the part most comparisons skip. Native human amylin is amyloidogenic. It spontaneously forms fibrils, which is why pramlintide (the approved amylin analog, Symlin) is a rat-sequence variant that requires an acidic formulation. Every modern amylin analog carries substitutions plus fatty-acid acylation to stay soluble and albumin-bound. In practical lab terms, the failure mode we see most with this peptide family isn't a fridge left open. It's shear-induced aggregation from vortexing or shaking during reconstitution. Let the solvent run down the vial wall and swirl gently.

What the published trial record actually shows

Cagrilintide has the deeper public dataset. A phase 2 dose-finding trial published in The Lancet in 2021 studied once-weekly cagrilintide over 26 weeks at doses up to 4.5 mg, reporting roughly 10.8% mean body weight reduction at the top dose against approximately 3.0% for placebo, with liraglutide 3.0 mg as an active comparator at around 9.0%. Its more prominent role now is combination work: CagriSema, which co-formulates cagrilintide with semaglutide 2.4 mg, reported approximately 22.7% mean weight reduction at week 68 in the REDEFINE-1 trial published in the New England Journal of Medicine in 2025.

Petrelintide is earlier and thinner on published data. Zealand Pharma has reported phase 1 multiple-ascending-dose findings and 2025 topline results from the ZUPREME-1 phase 2b programme, describing dose-dependent weight reduction with gastrointestinal events that were predominantly mild to moderate. Zealand also entered a global development partnership with Roche in 2025, which tells you how seriously the selective-amylin thesis is being taken. Full peer-reviewed phase 2b publication is what the field is waiting on.

One analytical warning, because this is where petrelintide vs cagrilintide discussions go wrong most often. Cross-trial comparison is the single most abused shortcut in metabolic peptide research. Different durations, different titration schedules, different baseline populations and different placebo responses make a 10.8% result and a 22.7% result non-comparable in any rigorous sense. These compounds are supplied for laboratory research only and are not for human or veterinary use. Anyone with questions about their own health or an animal's should speak with a physician or a veterinarian rather than extrapolating from trial data.

How amylin compounds stack up against the incretin agonists

The amylin pathway and the incretin pathway are not variations on the same theme. They're separate receptor systems with separate anatomy.

Petrelintide vs semaglutide is the cleanest illustration. Semaglutide is a GLP-1 receptor agonist acting largely through the hypothalamic arcuate nucleus with a plasma half-life of roughly seven days; STEP-1, published in NEJM in 2021, reported 14.9% mean weight reduction at 68 weeks on 2.4 mg weekly. Petrelintide works through calcitonin receptor and RAMP complexes in the brainstem instead, which is why amylin analogs are being studied as complements to incretins rather than replacements.

Petrelintide vs tirzepatide adds a second incretin receptor to the picture. Tirzepatide is a dual GIP and GLP-1 receptor agonist with a half-life of approximately five days; SURMOUNT-1, published in NEJM in 2022, reported 20.9% mean weight reduction at 72 weeks on 15 mg. Petrelintide vs retatrutide stretches the gap further still, since retatrutide is a triple GIP, GLP-1 and glucagon receptor agonist whose phase 2 results in NEJM in 2023 reported 24.2% mean weight reduction at 48 weeks at 12 mg, with glucagon receptor activity adding an energy-expenditure component amylin analogs don't have.

Petrelintide vs eloralintide is the genuine like-for-like matchup. Eloralintide (LY3841136, Eli Lilly) is also a selective amylin receptor agonist, and Lilly reported phase 2 data in 2025. Two selective amylin candidates from two large developers moving in parallel is the clearest signal available that the selectivity bet is the current frontier in this class.

Petrelintide vs cagrilintide: side-by-side compound comparison

This table maps receptor targets, dosing intervals used in trials and the most advanced publicly reported data for each compound. It exists to stop the apples-to-oranges comparisons that dominate forum discussion.

Compound	Receptor target	Trial dosing interval	Most advanced public data	Bottom line
Petrelintide (ZP8396)	Selective amylin receptor agonist, reduced calcitonin receptor activity	Once weekly	Phase 2b ZUPREME-1 topline reported 2025; Roche partnership	The purest test of the selectivity hypothesis, but the peer-reviewed record is still thin
Cagrilintide (AM833)	Non-selective amylin and calcitonin receptor agonist	Once weekly	Lancet 2021 phase 2 monotherapy; REDEFINE-1 combination data in NEJM 2025	Deepest amylin dataset available, though its future is mostly tied to combination work
Eloralintide (LY3841136)	Selective amylin receptor agonist	Once weekly	Phase 2 data reported 2025	The direct mechanistic rival to petrelintide, from a second major developer
Semaglutide	GLP-1 receptor agonist	Once weekly, half-life around 7 days	STEP-1, NEJM 2021, 14.9% at 68 weeks	Different receptor family entirely; the incretin benchmark everything is measured against
Tirzepatide	Dual GIP and GLP-1 receptor agonist	Once weekly, half-life around 5 days	SURMOUNT-1, NEJM 2022, 20.9% at 72 weeks	Dual incretin agonism, a separate mechanism from amylin signalling
Retatrutide	Triple GIP, GLP-1 and glucagon receptor agonist	Once weekly	Phase 2, NEJM 2023, 24.2% at 48 weeks	Adds glucagon-driven energy expenditure; the most mechanistically crowded of the group

What If: Amylin Analog Research Scenarios

What if a lyophilised amylin analog vial arrives at ambient temperature?

Document the excursion, check the shipping record and the certificate of analysis, then decide whether the material still fits the study's tolerance. Lyophilised peptides are far more thermally forgiving than reconstituted solution, and short ambient transit is standard across the industry. The unrecoverable damage happens after reconstitution, when solution held above 8°C can undergo changes in aggregation state that visual inspection will not reliably reveal.

What if the reconstituted solution looks hazy or shows visible strands?

Discard it and note the preparation conditions. Haze or fibrous strands in an amylin-family peptide are the visual signature of aggregation, which is exactly the behaviour native IAPP is known for. In our experience, the cause traces back to agitation or an incompatible solvent far more often than to storage temperature, so review the mixing technique before blaming the cold chain.

What if a study design needs a comparator arm for petrelintide vs cagrilintide?

Match the receptor pharmacology, not the headline percentages. Because cagrilintide engages calcitonin receptors and petrelintide is designed not to, any comparator arm needs assays capable of distinguishing the two receptor populations, otherwise the readout collapses into a single undifferentiated amylin effect. Confirm identity and purity against batch documentation before the first run.

The honest truth about ranking these two today

Let's be direct about this: nobody can credibly declare a winner in petrelintide vs cagrilintide right now, and anyone who does is reading marketing rather than data. Cagrilintide has the longer published record and a combination programme with results in a top-tier journal. Petrelintide has a mechanistic rationale that a major pharmaceutical partner found compelling enough to back, and phase 2b topline numbers that have not yet been fully peer reviewed. Those are different kinds of evidence at different stages of maturity. The selectivity question is genuinely unresolved, and pretending otherwise is how research assumptions get baked in before the data supports them.

If your work involves this class, provenance matters more than the compound name on the label. Every batch we ship comes with third-party certificates of analysis, and researchers comparing amylin and incretin pharmacology can review our cagrilintide listing alongside tirzepatide or browse the oral research compounds and the wider peptide catalog for adjacent study tools.

The petrelintide vs cagrilintide debate is really a preview of where this whole field is heading. For fifteen years the metabolic peptide story was about adding receptors, from GLP-1 to dual to triple agonism. The amylin work asks the opposite question: what happens when you subtract a receptor on purpose? If selective amylin agonism holds up in full publication, the next decade of combination design will be built on restraint rather than accumulation, and that's a much more interesting scientific bet than another percentage point on a weight curve.

References

Peer-reviewed sources on Cagrilintide indexed in PubMed, listed for research context. Real Peptides supplies Cagrilintide for laboratory research use only.

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. The American journal of cardiology, 2026. PMID 41759565. doi:10.1016/j.amjcard.2026.02.030
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian journal of endocrinology and metabolism, 2024. PMID 39676787. doi:10.4103/ijem.ijem_45_24
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. The lancet. Diabetes & endocrinology, 2026. PMID 42009015. doi:10.1016/S2213-8587(25)00402-4
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2025. PMID 40544433. doi:10.1056/NEJMoa2502081
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine, 2025. PMID 40544432. doi:10.1056/NEJMoa2502082
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine, 2025. PMID 40609154. doi:10.1016/j.ebiom.2025.105836
Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature communications, 2025. PMID 40204768. doi:10.1038/s41467-025-58680-y
In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk. Annals of internal medicine, 2025. PMID 41052437. doi:10.7326/ANNALS-25-03745-JC

Questions

The core difference is receptor selectivity. Cagrilintide is a non-selective amylin analog that activates both amylin receptors and the calcitonin receptor, while petrelintide is engineered as a selective amylin receptor agonist with reduced calcitonin receptor activity. Both are long-acting compounds studied at once-weekly intervals in trials, and both remain investigational rather than approved drug products.

Amylin doesn't have a standalone receptor. It signals through complexes formed when the calcitonin receptor pairs with receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3), producing the AMY1 to AMY3 subtypes concentrated in the brainstem area postrema. GLP-1 receptor agonists such as semaglutide act on a distinct receptor largely in the hypothalamic arcuate nucleus. Because the pathways are separate, research groups are studying amylin analogs as complements to incretins rather than substitutes.

Cagrilintide does, by a clear margin. Its phase 2 monotherapy dose-finding trial was published in The Lancet in 2021, and combination results for CagriSema appeared in the New England Journal of Medicine in 2025. Petrelintide has phase 1 data and a 2025 phase 2b topline announcement from Zealand Pharma, with full peer-reviewed publication still pending.

No. Both are research-use-only compounds supplied for laboratory investigation, and neither is an FDA-approved drug product for human or veterinary use. Anyone with a health question about themselves or an animal should speak with a physician or a veterinarian rather than drawing conclusions from research literature.

They belong to different receptor families. Tirzepatide is a dual GIP and GLP-1 receptor agonist with a half-life of roughly five days, and SURMOUNT-1 in NEJM reported 20.9% mean weight reduction at 72 weeks on 15 mg. Retatrutide adds glucagon receptor agonism to that pair, with phase 2 results in NEJM reporting 24.2% at 48 weeks at 12 mg. Petrelintide acts through amylin receptor complexes instead, which is why combination research pairing amylin analogs with incretins is an active direction.

Both are selective amylin receptor agonists in the same mechanistic class, which makes eloralintide (LY3841136, Eli Lilly) the closest direct comparator to petrelintide (ZP8396, Zealand Pharma). Lilly reported phase 2 data for eloralintide in 2025, and Zealand reported phase 2b topline for petrelintide in the same year. The differences that matter sit in molecular design details and pharmacokinetic profile rather than in the receptor target itself.

Aggregation is the dominant risk. Native human amylin is amyloidogenic and readily forms fibrils, so every analog in the class is engineered for solubility and remains sensitive to physical stress. Vortexing or shaking during reconstitution can trigger shear-induced aggregation that appears as haze or visible strands. Lyophilised material tolerates short ambient transit, but reconstituted solution should be held at 2 to 8°C and any batch with visible particulates should be discarded.

Research-grade peptides are supplied by specialist manufacturers to laboratories and institutional researchers, not through pharmacies. Pricing varies widely by synthesis complexity, sequence length, batch size and purity specification, so quoted figures differ substantially between suppliers. The variable worth scrutinising is documentation: third-party certificates of analysis confirming identity, purity and batch traceability separate research-grade material from unverified product.

Because amylin receptors are built from the calcitonin receptor, any amylin analog can engage the calcitonin receptor directly unless it's specifically designed not to. The hypothesis driving selective compounds is that calcitonin receptor engagement contributes to receptor desensitisation over time and to gastrointestinal tolerability burden. That hypothesis is the scientific basis of the entire selective amylin programme, and it has not yet been settled by head-to-head published evidence.

Cagrilintide has monotherapy phase 2 data from the 2021 Lancet trial, but its most visible development path is now the CagriSema combination with semaglutide 2.4 mg, which reported approximately 22.7% mean weight reduction at week 68 in REDEFINE-1. That shift toward combination development is itself informative: it suggests the field sees amylin agonism as an additive mechanism layered onto incretin action rather than a standalone replacement for it.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA